Sanctuary Advisors LLC raised its holdings in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 15.4% during the first quarter, according to its most recent filing with the SEC. The firm owned 45,881 shares of the financial services provider’s stock after purchasing an additional 6,112 shares during the period. Sanctuary Advisors LLC’s holdings in iShares Biotechnology ETF were worth $7,747,000 at the end of the most recent reporting period.
Other hedge funds have also recently modified their holdings of the company. Sigma Planning Corp increased its holdings in iShares Biotechnology ETF by 60.1% during the first quarter. Sigma Planning Corp now owns 10,031 shares of the financial services provider’s stock valued at $1,694,000 after buying an additional 3,766 shares during the period. Valmark Advisers Inc. raised its position in shares of iShares Biotechnology ETF by 3.2% in the 1st quarter. Valmark Advisers Inc. now owns 2,435 shares of the financial services provider’s stock worth $411,000 after acquiring an additional 75 shares in the last quarter. Midwest Trust Co lifted its stake in shares of iShares Biotechnology ETF by 37.8% during the 1st quarter. Midwest Trust Co now owns 4,894 shares of the financial services provider’s stock worth $826,000 after purchasing an additional 1,343 shares during the last quarter. Fifth Third Bancorp boosted its position in iShares Biotechnology ETF by 106.4% during the first quarter. Fifth Third Bancorp now owns 27,352 shares of the financial services provider’s stock valued at $4,618,000 after purchasing an additional 14,097 shares in the last quarter. Finally, Sovran Advisors LLC boosted its holdings in shares of iShares Biotechnology ETF by 18.9% in the 1st quarter. Sovran Advisors LLC now owns 1,490 shares of the financial services provider’s stock valued at $251,000 after buying an additional 237 shares in the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.
iShares Biotechnology ETF Stock Performance
Shares of IBB opened at $189.76 on Friday. iShares Biotechnology ETF has a twelve month low of $128.84 and a twelve month high of $199.05. The company has a 50 day moving average of $177.79 and a two-hundred day moving average of $173.40.
iShares Biotechnology ETF Cuts Dividend
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Read More
- Five stocks we like better than iShares Biotechnology ETF
- AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
- Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth
- TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident
- GE Aerospace Faces a Prove-It Moment in Q2 Earnings
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
